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Highly pathogenic avian inﬂuenza is an on-going problem in poultry and a potential human pandemic
threat. Pandemics occur suddenly and vaccine production must be fast and effective to be of value in
controlling the spread of the virus. In this study we evaluated the potential of a recombinant protein
from the extracellular domain of an H5 hemagglutinin protein produced in a yeast expression system to
act as an effective vaccine. Protein production was efﬁcient, with up to 200 mg puriﬁed from 1 L of
culture medium. We showed that the deletion of the multibasic cleavage site from the protein improves
oligomerization and, consequentially, its immunogenicity. We also showed that immunization with this
deleted protein protected chickens from challenge with a highly pathogenic avian inﬂuenza H5N1 virus.
Our results suggest that this recombinant protein produced in yeast may be an effective vaccine against
H5N1 virus in poultry.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Avian inﬂuenza (AI) is a highly infectious and economically
relevant disease affecting the poultry industry. It also remains axidase; Endo H, endoglycosi-
CS, multibasic cleavage site;
y; PAGE, polyacrylamide gel
y; DLS, Dynamic Light Scat-
on electron microscopy; SPF,
; HI, hemagglutination inhi-
ated animals; HexNAc, N-
and Professor Włodzimierz
Biosynthesis, Institute of
ces, Pawinskiego 5A, 02-106,
B.V. This is an open access article upotential public health threat. The recent avian inﬂuenza outbreak
in the United States led to the destruction of more than 40 million
birds, which caused huge economic losses (http://www.usda/
avian_inﬂuenza.html). All control programs for AI share three
broad approaches: prevention, good management and eradication
(Swayne, 2012). Vaccines are one tool that may be used in an
outbreak to support the eradication of the virus because they boost
immunity and decrease virus shedding into the environment.
Current licensed vaccines are mainly based on inactivated whole AI
viruses. However their application is limited by the difﬁculty in
differentiating infected from vaccinated animals (DIVA) since both
have the same antibodies. Recently new generation vaccines have
been developed that induce antibodies solely to hemagglutinin
(HA),thus facilitating the application of DIVA strategy by using a
serological test that detects antibodies to antigens other than HA,
so providing evidence for ﬁeld infection (Swayne and Kapczynski,
2008; Lee et al., 2014). Among these vaccines the recombinant
fowlpox-AI-H5 and recombinant herpesvirus-turkey-AI-H5nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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fowlpox-AI-H5 vaccine can only be used in chickens which must be
naïve to the fowl pox vector (Swayne et al., 2000). Since the anti-
bodies neutralizing the inﬂuenza virus are mainly directed against
the HA protein, a dynamic development in subunit vaccine research
is currently being observed.
It is a great challenge, using recombinant technology, to produce
a properly folded HA protein required for optimal immunogenicity.
Hemagglutinin is synthesized as a precursor polypeptide (HA0).
This protein is cleaved by proteases to create two subunits, HA1 and
HA2, linked by a disulﬁde bond. HA is post-translationally modiﬁed
by glycosylation that was shown to play an important role in a
proper folding and trimer stabilization (Copeland et al., 1986;
Roberts et al., 1993; Sun et al., 2013). On the surface of virions,
the trimeric HA is stabilized mainly by residues from the HA2 re-
gion (Eisenberg and McLachlan, 1986; Wilson and Cox, 1990).
Structurally, the hemagglutinin ectodomain is composed of two
distinct regions: (1) a long ﬁbrous stem region, containing residues
from both HA1 and HA2 (2) a globular head region containing
residues entirely from HA1. Although most of the antibodies
neutralizing the inﬂuenza virus are directed mainly against the
variable globular head of hemagglutinin (Wiley et al., 1981), the
HA2 region was also reported to induce neutralizing antibodies
(Russ et al., 1987; Gocnik et al., 2008; Pica et al., 2012). These
ﬁndings suggest that a vaccine based on the extracellular domain of
HA would be effective against inﬂuenza virus infections.
Another important part of the HA protein is the cleavage site
between the HA1 and HA2 domain. The sequence of amino acids in
the HA0 cleavage site differs among the virus strains and this is a
determining factor of viral pathogenicity (Steinhauer, 1999; Senne
et al., 1996). The highly pathogenic avian inﬂuenza (HPAI) viruses
of the H5 and H7 subtypes contain a multibasic cleavage site
(MBCS) motif (Munster et al., 2010). HPAI viruses can be trans-
mitted to humans as well as other mammals (Kuiken and
Taubenberger, 2008; Reperant et al., 2009). It has been reported
that the modiﬁcation of MBCS of the H5 HA to a single basic amino
acid attenuates viral pathogenicity but preserves the antigenicity of
the hemagglutinin protein (Subbarao et al., 2003).
We recently demonstrated that recombinant inﬂuenza H5 pro-
tein produced in Pichia pastoris induced a strong immunological
response in mice, even though it was cleaved into two subunits
(Kopera et al., 2014). The P. pastoris system was chosen because of
its many advantages. It has been extensively utilized as an indus-
trial platform to produce various proteins of interest, including
vaccine antigens (Shanvac™, Elovac™, Gavac™). Pichia cells offer
the possibility of producing a high level of the desired recombinant
protein, are able to carry out post-translational modiﬁcations (such
as glycosylation and the disulﬁde bond formation) and in addition
efﬁciently secrete heterologous protein into the culture medium
which greatly facilitates its subsequent puriﬁcation. In the current
study, we show that deletion of MBCS in the extracellular region of
the H5 antigen improves protein oligomerization. Further, we
demonstrate that such a modiﬁed antigen is more immunogenic
than HA with MBCS, and protects from a lethal challenge with the
H5 subtype of HPAI.
2. Materials and methods
2.1. Expression of H5N1 hemagglutinin in P. pastoris
The H5N1 strain A/swan/Poland/305-135V08/2006 clade 2.2.2
(EpiFluDatabase Accession No. EPI15789) was the source of HA
gene GenBank accession number: KC172926. The DNA fragment
encoding the extracellular domain of HA (Fig. 1) was ampliﬁed
using forward and reverse primers containing Cla and SacIIrestriction site, respectively. The cleavage site (MBCS, aminoacids
RRRKKR) in the hemagglutinin sequence of the inﬂuenza H5N1
virus was deleted in a two-step site-directed mutagenesis reaction.
The extracellular domain (H5DH and H5DHD) was cloned into
pPICZaC in frame with a-factor. The His-Tag sequence was added at
the C-terminus using the reverse primer. Obtained constructs
pPICZaC/H5DH and pPICZaC/H5DHD were introduced by electro-
poration into the P. pastoris KM 71 strain (Invitrogen, USA). The
yeast transformants were screened for insertion by PCR using 5
0
AOX I and 3
0
AOX I primers. Yeast clones with veriﬁed inserts were
grown as previously described (Kopera et al., 2014). Brieﬂy, the
positive transformants were inoculated in 100 ml or 400 ml of BMY
medium with 1% glycerol and were grown at 30 C on a plate
agitator at 200 rpm agitation. After 48 or 72 h cells were harvested
by centrifugation and resuspended in one/fourth of the original
volume of BMY with 5% methanol. Subsequent incubation at 26 C
with vigorous shaking was continued for 7 days.
2.2. Puriﬁcation of H5DH and H5DHD proteins
Recombinant hemagglutinins were puriﬁed from the culture
medium. Protein binding to Ni-NTA Agarose (Qiagen, Germany)
was carried out in PBS pH 7.8 with additional 400 mMNaCl. The HA
proteinwas eluted from the columnwith 250 mM imidazole in PBS
pH 7.4. Protein amount was determined using the Bradford method
(Bio-Rad, USA). The HA proteins were dialyzed against PBS pH 7.4
followed by lyophilization and stored at 20 C. The H5DH and
H5DHD proteins were analyzed using 4e12% SDS-PAGE (Bio-Rad,
USA) and by 12% Native-PAGE. H5DH and H5DHD proteins (50 mg)
were analyzed by High Performance Liquid Chromatography (HPLC,
Breeze, Waters, UK) on a C4 column (250  4.6 mm, ACE, UK). The
eluting solvent A was 0.1% triﬂuoroacetic acid/water, and solvent B
was 0.1% triﬂuoroacetic acid/90% acetonitrile/water. A linear
gradient from 0% B to 100% B in 100 min at a ﬂow rate of 1 ml/min
was applied, with dual detection at 220 and 280 nm.
2.3. MS/MS analysis of H5DHD protein
H5DHDHis6 protein was denatured with denaturing buffer at
95 C for 10min. The reaction mix containing denatured HA protein
and 0.125 U of endoglycosidase H (Endo H, New England Biolabs,
USA) was incubated at 37 C for 1 h. The non treated protein sample
was used as a control. The protein was analyzed using SDS-PAGE.
The gel band containing deglycosylated polypeptides was excised.
The protein was reduced with 100 mM 1,4 Dithiothreitol (30 min,
56 C), alkylated with 0.5 M iodoacetamide (45 min in the dark,
room temperature) and digested overnight with trypsin
(sequencing Grade Modiﬁed Trypsin e Promega, USA) by adding
the enzyme directly to the reaction mixture. Peptides were
analyzed by LC-MS-MS/MS (liquid chromatography coupled to
tandem mass spectrometry) using the Nano-Acquity (Waters, UK)
LC system and the Orbitrap Velos mass spectrometer (Thermo
Electron Corp., USA) as previously described (Kopera et al., 2014).
Fragmentation spectra of peptides indicated by Mascot as N-gly-
cosylated were manually investigated.
2.4. Characterization of H5DHD antigen
H5DHD at a concentration of 0.5 mg/ml was loaded on a
Superdex 200 10/300 GL column (GE Healthcare, UK), pre-
equilibrated with 10 mM Tris pH 7.8 with 200 mM NaCl and the
protein elution was monitored at 280 nm. Molecular weight stan-
dards (Bio-Rad, USA) were used to calibrate the column and to
identify the molecular weights of proteins present in the samples.
Dynamic Light Scattering measurements of the puriﬁed H5DHD
Fig. 1. Schematic diagram of the HA protein and two constructs e H5DH and H5DHD. SP e signal peptide, TM e transmembrane domain, CT e cytoplasmic domain, MBCS e
multibasic cleavage site. The schematic trimer structure was modelled from the PDB ID code 5E2Y in the YASARA program.
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(Wyatt Technology Corp., USA). Selected fractions containing high
molecular weight forms (HMW) and low molecular weight forms
(LMW) of H5 protein from the SEC analysis were dilutedwith buffer
(10 mM Tris pH 7.8, 200 mM NaCl) to 0.1e1.0 mg/ml, and spun
down at 20,000g for 5 min. All measurements were taken at 25 C
in 50 ml disposable cuvettes (UVette, Eppendorf, USA) with a 5 s
acquisition time and 10 acquisitions per measurement. The
collected data was analyzed on the DYNAMICS v7 software (Wyatt
Technology Corp., USA). The H5DHD protein sample was applied to
the clean side of carbon onmica and negatively stained with 2% (w/
v) sodium silico tungstate. A grid was then placed on top of the
carbon ﬁlm which was subsequently air-dried.
Images were taken under low dose conditions (less than 20 e-/
A2) with a T12 FEI electron microscope at 120 kV using an ORIUS
SC1000 camera (Gatan, Inc., Pleasanton, CA).
2.5. Ethic statements
The experiments were approved by the Second Local Ethical
Committee for Animal Experiments at the University of Life Sci-
ences in Lublin, Permit No. 70/2013. All procedures were according
to Regulation of the Minister of Agriculture and Rural Development
on the Speciﬁc Conditions of Keeping Animals in Laboratory Animal
Farms and in Entities Carrying out Experiments and Tests and the
performance of experiments on animals were governed by the Act
on Experiments on Animals (Polish Law, 2005). All the chickens
were raised and handled humanely. All efforts were made to
minimize suffering. The chickens were monitored two times a day,
including weekends. At the end of experiment the chickens were
humanely euthanized (cervical dislocation).
2.6. Chicken immunization
Layer chickens (ISA brown) were housed in poultry-house in
cages, in standard commercial conditions. Groups of ten chicken
were immunized subcutaneously in the neck skin fold twice at the
21st and 49th day of life with 25 mg of H5DH or H5DHD supple-
mented with 0.3% Alhydrogel (aluminium hydroxide, Gentaur,Germany). The control group received only adjuvant according to
the same schedule. Four weeks after booster blood was collected
from the wing veins, allowed to coagulate, and centrifuged. The
collected sera were kept at 80 C. For the wild-type H5N1 chal-
lenge study, ten speciﬁc pathogen free (SPF) White Leghorn
chickens (VALO BioMedia GmbH, Germany), housed in a biosafety
level 3 containment, were immunized subcutaneously into the
neck skin fold with 25 mg of H5DHD protein. The recombinant
antigen suspended in PBS was supplemented with 0.3% Alhydrogel.
Control group (5 chickens) was only administered speciﬁc adjuvant
according to the same schedule. Re-vaccination was carried out 4
weeks later as described above. Prior to challenge, the chickens
were placed in HEPA-ﬁltered isolators (Montair Andersen B.V.,
Netherlands).
2.7. ELISA
The 96-well polystyrene plates (Nunc, Denmark) were coated
overnight at 4 C with recombinant H5 HA (A/Bar-headed Goose/
Qinghai/12/05 H5N1, clade 2.2) produced in a mammalian cell
system (Immune Technology, USA) diluted in PBS to 6 mg/ml. Bound
IgY were detected using goat anti-chicken IgY (Fc-speciﬁc)-HRP
(Thermo Scientiﬁc, USA) antibodies. After incubation with TMB
chromogen substrate solution (Sigma-Aldrich) absorbance was
measured at 450 nm (A450) with a microplate reader (Synergy 2,
BioTek Instruments). The cut off for the ELISA was set as the mean
A450 of the control group plus two standard deviations.
2.8. Challenge studies
The immunized chickens as well as control birds were inocu-
lated oculonasally with 106 50% egg infectious dose (EID50) of the
H5N1 A/turkey/Poland/35/2007 (clade 2.2.3, isolated in 2007 from
a meat turkey ﬂock in Poland) virus in the volume of 100 ml
intraocularly (50 ml) and intranasally (50 ml). Clinical observation
was performed twice daily. Oropharyngeal and cloacal swabs were
collected from all birds at 4, 7, 10 and 14 days post inoculation and
in the case of control birds only at 3 days post inoculation. RNAwas
extracted from 0.2 ml of the transport medium using a NucleoSpin
Fig. 3. Analytical HPLC chromatograms of H5DH and H5DHD protein. Absorbance at
220 nm is shown. A volume corresponding to 50 mg of protein was injected onto ACE
C4 column as described in Materials and methods.
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mated workstation (PerkinElmer). RT-PCR/M with primers devel-
oped by Spackman et al (Spackman et al., 2008). and Quantitect
Probe PCR reagents (Qiagen, USA) was performed. Ten-fold di-
lutions of the RNA extracted from allantoic ﬂuids collected from SPF
eggs inoculated with a titrated homologous H5N1 virus were also
tested. The results of the qRT-PCR were converted from cycle
threshold values and expressed as equivalent EID50 per milliliter of
swab medium. At the end of the experiment, the chickens that
survived infection with virulent virus were euthanized by cervical
dislocation.
2.9. Hemagglutation inhibition test
Two and four weeks post prime vaccination, two and three
weeks post booster and two week after challenge, samples of sera
were collected from birds and tested in a hemagglutination-
inhibition (HI) test. The HI test was performed according to a
standard procedure (OIE, 2015). Brieﬂy, 10 ml of sera in serial
twofold dilutions were incubated for 25e30minwith four HA units
of the inactivated antigen A/turkey/Poland/35/2007 H5N1. Next, a
1% suspension of chicken erythrocytes was added and incubated for
30 min. The HI titer was assessed as the reciprocal of the highest
dilution in which hemagglutination was inhibited.
3. Results
3.1. Characterization of glycosylated hemagglutinin variants
The extracellular domain of H5N1 hemagglutinin (residues 17-
531) was selected because it was previously shown to induce a
strong immunological response in mice (Kopera et al., 2014).
Therefore we presumed that the recombinant protein encom-
passing these residues may adopt the correct three-dimensional
structure required for trimer formation and/or higher oligomeri-
zation. The transmembrane region and cytoplasmic tail of HA2
were excluded in order to favour secretion of the protein into the
culture medium. In order to obtain uncleaved protein product we
excluded the 18 nucleotides coding for the MBCS site. Finally we
obtained two variants of the H5 antigen: H5DH (residues 17-531)
and H5DHD (residues 17-531, D341-346, amino acids RRRKKR
excluded) (Fig. 1). Coomassie blue staining after the SDS-PAGE
separation of the puriﬁed H5DH and H5DHD protein showed a
high level of purity after one-step puriﬁcation (Fig. 2A and B). TheFig. 2. Electrophoretic analysis of H5DH and H5DHD after the one step IMAC puriﬁcation.
containing molecular weight marker (M), 15 ml of eluted protein (E) were electrophoresed in
PAGE analysis disrupted all disulphide bonds (e.g. between cysteine 4 and cysteine 461) an
their different glycosylation states. Fractions of H5DH and H5DHD protein and bovine serupurity of the proteins was further conﬁrmed by HPLC (Fig. 3). Both
SDS-PAGE and HPLC analysis indicated that the H5DHD proteinwas
produced as an uncleaved polypeptide, while H5DH was proteo-
lytically processed into separate domains (HA1 and HA2). Analysis
of the HA (A/swan/Poland/305-135V08/2006) sequence deter-
mined six potential N-glycosylation sites (5 sites in HA1 and 1 site
in HA2) in the extracellular domain of HA protein using NetNGlyc
server (http://www.cbs.dtu.dk/services/NetNGlyc/). In order to
examine N-glycosylation sites of recombinant HA antigens we used
a standard proteomic procedure for Endo H treated proteins. Mass
spectrometry analysis conﬁrmed that all predicted N-glycosylation
sites in H5DH (Kopera et al., 2014) and three sites in H5DHD
(Table 1) are glycosylated.
Yields as high as 20 mg and 200 mg of ﬁnal puriﬁed recombi-
nant antigen per 1 L were obtained after the IMAC procedure for
H5DH and H5DHD, respectively. Repeated production batches
indicated excellent reproducibility.
3.2. Immunogenicity of H5DH and H5DHD antigens
To identify potential differences of the responses in the two
groups (H5DH and H5DHD) sera of the individual birds were tested.Fractions of H5DH (A) and H5DHD (B) protein were analyzed by SDS-PAGE. Samples
12% SDS-PAGE gel and stained with Coomassie Blue. Reducing conditions during SDS-
d visualized bands of both HA1 and HA2 domains. Two forms of HA2 domain suggest
m albumin (BSA) were also analyzed under native condition.
Table 1
N-glycosylated peptides from the H5DHD protein conﬁrmed by LC/MS/MS analysis.
N-linked glycosylation sites are underlined. Molecular mass of modiﬁed peptides
(one HexNAc attached to the asparagine residue) was determined by spectrometer.
Residue Region Amino acid sequence Mass
22e35 HA1 NVTVTHAQDILEK þ HexNAc 1669.85
163e189 HA1 SYNNTNQEDLLVLWGIHHPNDAAEQTR þ HexNAc 3337.56
500e513 HA2 NGTYDYPQYSEEAR þ HexNAc 1894.78
HexNAc (N-acetylhexoseamine).
N-linked glycosylation sites are bolded and modiﬁed asparagine residues are
underlined.
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using an indirect ELISA and the hemagglutination inhibition (HI)
test. Both variants of H5 antigen elicited speciﬁc anti-HA-IgY anti-
bodies and only minor differences between these two antigens
were observed (Fig. 4A). However, the signiﬁcant differences in the
immunological properties between these two antigens were dis-
closed in the HI test. Only 50% of the group immunized with H5DH
were HI positive and no titers higher than 64 were observed,
whereas 100% of chicken immunized with H5DHD were positive
with higher HI titers (Fig. 4B). These results prompted us to
investigate the oligomeric status of H5DH and H5DHD antigens.3.3. H5DHD but not H5DH forms of higher oligomers
Electrophoresis under native conditions showed the high mo-
lecular weight forms in the sample of H5DHD (Fig. 2). Although
under native condition the H5DH protein migrated as a whole
molecule (under non-reducing conditions disulphide bonds areFig. 4. Chickens response after immunization with H5DH and H5DHD antigen. Immune resp
weeks after booster by indirect ELISA (A) and HI test (B).preserved), this variant of antigen formed only dimers. The H5DHD
antigen was further analyzed by size exclusion chromatography
(SEC) revealing two major peaks (Fig. 5A). The ﬁrst peak eluting
prior to a thyroglobulin (670 kDa) demonstrates that the recom-
binant antigen forms highmolecular weight complexes. The second
peak eluting between g-globulin (158 kDa) and ovalbumin (44 kDa)
indicates the presence of monomers or dimers. To assess the olig-
omeric proﬁle of the HMWand LMW fraction after a lyophilization/
resuspension cycle, we re-analyzed them separately. Both SEC-
puriﬁed fractions remain stable (Fig. 5B and C). SEC-puriﬁed frac-
tions were also analyzed using Dynamic Light Scattering (DLS). DLS
data showed that for the HMW fraction the measured size corre-
sponded to multimeric protein particles with an average hydro-
dynamic radius (Rhyd) of 30 nm. The average size of the particles
eluting in the LMW fraction was 10 nm. In order to establish
whether H5DHD protein forms biological nanostructures in a form
of subviral particles electron microscopy analysis was performed.
Transmission electron microscopy (TEM) showed that HMW olig-
omers formed regular, spherical-shaped nanostructures with an
average size of 30 nm in diameter (Fig. 6). The size of the particles is
consistent with the data obtained using DLS (Rhyd 30 nm). How-
ever, the morphology of H5DHD nanostructures visualized by TEM
is variable.3.4. H5DHD antigen protects from lethal H5N1 challenge
Our results strongly suggest that deletion of the MBCS motif in
the H5 protein improves its oligomerization and immunogenicity.
Thereforewe selected the H5DHD protein to evaluate the protective
efﬁcacy of a recombinant vaccine. Serological examination usingonse of individual chicken immunized with 25 mg of H5DH or H5DHDwere measured 4
Fig. 5. Characterization of H5DHD oligomers and monomers by Size Exclusion Chro-
matography on Superdex 200 10/300 GL column. (A) Chromatogram of the IMAC -
elution fraction (blue line). Molecular weight standard indicated by the magenta
dotted line. Fractions of the H5DHD protein were lyophilized separately and dissolved
in water followed by re-injection onto Superdex 10/300 GL column. The panels present
superimposed elution proﬁles of puriﬁed H5DHD protein (dotted line) overlaid with
SEC proﬁle of stable oligomers (B) and monomers (C). (For interpretation of the ref-
erences to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
Fig. 6. Transmission electron microscopy of the puriﬁed H5DHD protein. Images were
obtained at nominal 30 000 magniﬁcation. The black scale bar represents 100 nm.
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after SPF chicken immunization with H5DHD antigen. Kinetics of
the HI titer is presented in Fig. 7. Two weeks after the ﬁrst vacci-
nation the HI response was rather weak and only 50% of the group
were HI positive. Twoweeks later the immunological response had
increased and 9/10 chickens were HI positivewith antibody titer no
higher than 64 (Mean log2 4.4 ± 0.97). The second vaccination
boosted the antibody levels (Mean log2 6.1 ± 0.99) and all chickens
had seroconverted. HI titers as high as 4096 were observed after
challenge (log2 9.6 ± 1.35). All vaccinated chickens survived chal-
lenge and no clinical signs were observed whereas control chickens
died by 4 days post inoculation. High amounts of viral RNA (usually
>106 eqEID50 per ml swab ﬂuid) were detected in samples collected
from control birds. Only in three of ten immunized birds were small
amounts of the virus detected (103e105 eqEID50 per ml of swab
ﬂuid) in oropharyngeal and cloacal swabs (4 and 10 days post
inoculation).
4. Discussion
For effective poultry vaccination a low-cost vaccine with a
speciﬁc match to the antigen(s) of the responsible virus is strongly
required. Recombinant hemagglutinin-based vaccines are a po-
tential alternative for inﬂuenza vaccine manufacture. Here, we
investigated the use of the P. pastoris expression system to produce
a soluble HA antigen, which is the primary target of the neutralizing
antibody. We demonstrated the feasibility of producing H5N1 HA
antigen in yeast, that would allow rapid scale-up to high-volume
production. Using simple fed-batch growth procedures we ob-
tained high-level protein expression reaching 200 mg of the puri-
ﬁed H5DHD antigen from 1 L of yeast medium. A difference in the
expression levels between the H5DH and H5DHD proteins was
observed. The reason is unknown but it might be caused by the
differences in protein processing involving folding and glycosyla-
tion. However, further studies are needed to address this question.
One crucial issue for a veterinary sub-unit vaccine is the
development of a simple and efﬁcient process for puriﬁcation of the
desired antigen. The vaccine should ideally contain only desired
compound andmust be consistent in its composition. The P. pastorisFig. 7. A box-and-whisker plot showing kinetics of serum hemagglutination inhibition
(HI) titers in chicken following prime and booster immunization and after challenge
with homologous H5N1 strain (clade 2.2.3). The median (thick line) is shown with the
interquartile range (25% and 75%, box) and the maximum and minimum (whiskers),
n ¼ 10.
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considerably facilitates puriﬁcation of the product. Taking advan-
tage of this secretion and applying afﬁnity chromatography to the
growth medium from which the yeast cells had been removed we
managed to purify the H5DHD antigen to homogeneity in a one-
step process.
The design of effective vaccines for the prevention of inﬂuenza is
a challenging task. We selected residues 17 to 531 of H5 protein
representing the extracellular domain because it was reported to
induce a strong immunological response in mice (Kopera et al.,
2014; Shoji et al., 2009). We tested two variants of the H5 anti-
gen. Both H5DH and H5DHD were immunogenic in the chicken
model. This is consistent with a previous study in which the
modiﬁcation of MBCS of H5HA to a single basic residue failed to
alter the antigenicity of HA (Subbarao et al., 2003). It was also re-
ported that inﬂuenza VLPs containing mutant HA without the
multibasic cleavage site displayed an uncleaved precursor confor-
mation and elicited immune responses comparable to VLPs con-
taining wild type HA (Song et al., 2010). Our study demonstrated
that only the H5DHD antigen elicited high HI titers. Analysis of the
oligomerization status of H5DH and H5DHD antigen revealed that
deletion of the MBCS improves protein oligomerization. We
demonstrated that H5DHD formed oligomers with no requirement
for the addition of any foreign trimerization sequence. It was re-
ported that the expression of the recombinant HA ectodomain in
mammalian cells or the baculovirus system required the addition of
multimerization ‘foldon’ at the C terminus in order to produce a
stable oligomeric structure (Wei et al., 2008; Weldon et al., 2010).
Wei and colleagues analyzed various forms of rHA protein for their
potential efﬁcacy as vaccines (Wei et al., 2008). They reported that
different rH5HA proteins vary in their ability to elicit neutralizing
antibodies depending on their multimeric nature. High-molecular
weight oligomers stimulated the strongest antibody response, fol-
lowed by the trimeric form of the H5HA molecule, while H5HA
monomers were poorly immunogenic. On the other hand, despite
being monomeric, the H3HA protein expressed in the P. pastoris
was protective against a lethal inﬂuenza challenge in mice (Saelens
et al., 1999).
Transmission electron microscopy visualized H5DHD particles
with the average size of 30 nm that morphologically resembled
inﬂuenza virions. Pushko and colleagues showed that puriﬁed full-
length HA formed oligomeric pleomorphic subviral particles of
20 nm in diameter (Pushko et al., 2015). It was also reported that
the oligomeric fraction of rHA1 forms rosette-like structures
(Verma et al., 2012). For the ﬁrst time we showed that the H5DHD
protein that comprised the extracellular domain of hemagglutinin
assembled into spherical structures. However, the mechanism of
the H5DHD subviral particles formation remains to be elucidated.
The chicken model has been commonly used to evaluate the
virulence and the pathogenicity of the avian inﬂuenza viruses as
well as vaccine effectiveness. The assessment of protection by avian
inﬂuenza vaccines is best accomplished using a challenge model.
Vaccine efﬁcacy can be quantiﬁed by measuring the prevention of
morbidity and mortality, prevention of egg production drops and
quantitative reduction in shedding of the challenge virus (Swayne,
2009). In the challenge experiment the H5DHD antigen proved to
be strongly immunogenic for SPF chickens, which mounted satis-
factory level of antibodies and were fully protected against chal-
lenge with homologous H5N1 strain (clade 2.2.3) that is slightly
different from the original strain (clade 2.2.2). It should be pointed
out that aminimum of 80% protection frommortality is sufﬁcient in
efﬁcacy requirements for a vaccine in countries where vaccination
against avian inﬂuenza is permitted (OIE, 2015). Virus shedding
was also signiﬁcantly reduced compared to sham-vaccinated con-
trols. Only small amounts of virus in three of ten vaccinatedchickens were found in oropharyngeal and cloacal swabs. It is well
known that vaccines against highly pathogenic avian inﬂuenza vi-
ruses reduce sickness, clinical signs and death, but they would not
completely prevent birds from becoming infected and shedding
virus into the environment (USDA, Avian Inﬂuenza).
In summary, the H5 antigen based on the extracellular region of
hemagglutinin with deletion of the multibasic cleavage site oligo-
merizes into functional spherical-like structures. H5DHD is highly
immunogenic and provides clinical protection following a chal-
lenge with a homologous strain. The presented data demonstrated
that the inﬂuenza antigen efﬁciently produced in P. pastoris can be
considered as a candidate for a subunit vaccine.
5. Conclusion
The H5DHD antigen expressed by yeast contains a high pro-
portion of oligomeric antigen that appears to be an effective vac-
cine. When it is combined with the appropriate adjuvant it
generates high-afﬁnity antibodies with the capacity to neutralize
the homologous strain. A high level of production and ease of
differentiating infected from vaccinated animals (DIVA) are the
major advantages of this vaccine candidate.
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